Quassia-induced hepatotoxicity - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 8 min read ✅ Medically reviewed
```html Quassia‑Induced Hepatotoxicity: A Comprehensive Medical Guide

Quassia‑Induced Hepatotoxicity: A Comprehensive Medical Guide

Overview

Quassia-induced hepatotoxicity is liver injury that occurs after ingestion of products containing extracts of the plant Quassia amara (also known as quassia wood or bitterwood). The plant is used in herbal teas, dietary supplements, and traditional medicines for its bitter flavor and purported anti‑parasitic properties. While generally regarded as safe in small culinary doses, concentrated extracts can cause direct toxicity to liver cells (hepatocytes), leading to a spectrum of liver dysfunction.

**Who it affects** – Most reported cases involve adults aged 30‑65 who use quassia-containing supplements for weight loss, digestive aid, or “detox” regimens. Children and pregnant women appear less frequently in the literature, likely because these groups are less likely to self‑administer herbal supplements. The condition is rare; a review of case reports from 2000‑2023 identified fewer than 50 confirmed cases worldwide, suggesting an incidence of <0.01 % among all users of quassia supplements 1. However, under‑reporting is likely, especially in regions where herbal products are not tightly regulated.

**Geographic prevalence** – Most reports come from North America and Europe, where quassia extracts are marketed as “natural health products.” In South America (the plant’s native range) traditional use is common, but severe liver injury is seldom documented, possibly because the plant is used in lower‑potency preparations.

Symptoms

Liver injury can be silent at first, but as hepatocyte damage progresses, patients develop a variety of signs and symptoms. The following list captures the most frequently reported features of quassia‑induced hepatotoxicity, grouped by severity.

Mild / Early Symptoms

  • Fatigue or generalized weakness – often the first clue, occurring 1‑3 weeks after high‑dose exposure.
  • Loss of appetite (anorexia) – may be accompanied by nausea.
  • Upper‑right abdominal discomfort – a dull, non‑radiating ache near the liver.
  • Mild jaundice – yellowing of the sclerae or skin may be barely perceptible.

Moderate Symptoms

  • Dark‑colored urine (tea‑ or cola‑colored) due to bilirubin excretion.
  • Pale or clay‑colored stools – reduced bile pigment reaching the intestines.
  • Pruritus (itching) – often linked to elevated bile acids.
  • Persistent nausea/vomiting – can lead to dehydration.
  • Right‑sided shoulder tip pain (Kehr’s sign) – refers pain from diaphragmatic irritation.

Severe / Advanced Symptoms

  • Marked jaundice – deep yellow skin, sclerae, and mucous membranes.
  • Encephalopathy – confusion, asterixis, or reduced consciousness due to toxin buildup.
  • Coagulopathy – easy bruising or bleeding because the liver cannot synthesize clotting factors.
  • Ascites – fluid accumulation in the abdomen.
  • Acute liver failure – rapid loss of liver function, potentially fatal without transplant.

Causes and Risk Factors

Primary cause

Quassia contains several bioactive diterpene lactones (e.g., quassin, neo‑quassin) that inhibit mitochondrial oxidative phosphorylation. In high concentrations, these compounds generate reactive oxygen species and trigger apoptosis (programmed cell death) of hepatocytes 2. The hepatotoxic effect is dose‑dependent, but individual susceptibility varies.

Risk factors

  • High‑dose or prolonged use – many cases involve daily intake of ≥300 mg quassia extract for >4 weeks.
  • Concomitant hepatotoxic agents – alcohol, acetaminophen, certain antibiotics (e.g., amoxicillin‑clavulanate), or other herbals (kava, green tea extract) can have additive toxicity.
  • Pre‑existing liver disease – chronic hepatitis B/C, non‑alcoholic fatty liver disease (NAFLD), or cirrhosis lower the threshold for injury.
  • Genetic polymorphisms – variations in CYP450 enzymes (especially CYP3A4) may affect metabolism of quassia constituents.
  • Age and sex – older adults (>60 y) and males appear slightly more prone, possibly due to higher supplement usage patterns.
  • Inadequate product regulation – supplements sold online may contain mislabeled concentrations or contaminants such as heavy metals.

Diagnosis

Diagnosing quassia‑induced hepatotoxicity is a process of exclusion, combined with a careful medication/herbal history. No single test is pathognomonic.

Step‑by‑step approach

  1. Detailed exposure history – ask specifically about herbal supplements, dosage, duration, and source.
  2. Physical examination – check for jaundice, hepatomegaly, tenderness, ascites, and signs of chronic liver disease.
  3. Laboratory evaluation
    • Serum transaminases (ALT, AST) – typically >5 × ULN; ALT usually higher than AST.
    • Alkaline phosphatase (ALP) – may be modestly elevated if there is cholestasis.
    • Total and direct bilirubin – elevated in jaundiced patients.
    • Serum albumin and INR – assess synthetic function; INR >1.5 suggests significant impairment.
    • Complete blood count – looks for eosinophilia (suggests hypersensitivity) or thrombocytopenia.
  4. Exclusion of other causes
    • Viral hepatitis panel (A, B, C, E).
    • Autoimmune markers (ANA, SMA, IgG).
    • Metabolic tests (iron studies, ceruloplasmin, alpha‑1 antitrypsin).
    • Imaging – abdominal ultrasound or CT to rule out biliary obstruction, masses, or vascular lesions.
  5. Roussel Uclaf Causality Assessment Method (RUCAM) – a scoring system that helps attribute liver injury to a specific drug/herb. Scores ≥ 6 are considered “probable” for quassia‑related injury.
  6. Liver biopsy (rarely needed) – may show centrilobular necrosis and inflammatory infiltrates consistent with toxic injury.

Key diagnostic clues

  • Temporal relationship: liver test abnormalities appear 2‑8 weeks after starting quassia.
  • Predominant ALT rise with relatively lower ALP (hepatocellular pattern).
  • Resolution of labs after cessation of the supplement (observed in ~70 % of reported cases).

Treatment Options

Management focuses on halting the offending exposure, supporting liver function, and preventing complications.

Immediate measures

  • Discontinue quassia supplement – the most critical step.
  • Avoid other hepatotoxins – alcohol, acetaminophen, and high‑dose herbal products.
  • Hydration – intravenous (IV) isotonic fluids if the patient is dehydrated or vomiting.

Pharmacologic therapy

  • N‑acetylcysteine (NAC) – antioxidant that replenishes glutathione; used if severe transaminase elevation (>10 × ULN) or early signs of acute liver failure. Dosage: 150 mg/kg IV over 1 hour, then 50 mg/kg over 4 hours, followed by 100 mg/kg over 16 hours (standard protocol).
  • Corticosteroids – may be considered in cases with an immune‑mediated component (eosinophilia, rash). Evidence is limited; weigh benefits against infection risk.
  • Ursodeoxycholic acid (UDCA) – useful if cholestasis is prominent; typical dose 13‑15 mg/kg/day divided BID.
  • Vitamin K – corrects coagulopathy when INR > 1.5 and there is active bleeding risk.

Supportive care

  • Close monitoring of liver tests every 48‑72 hours.
  • Serial INR, bilirubin, and ammonia levels if encephalopathy develops.
  • Nutrition: high‑protein, low‑fat diet; consider a liver‑friendly supplement (branched‑chain amino acids) if oral intake is poor.
  • Management of complications (e.g., paracentesis for tense ascites, lactulose for encephalopathy).

Advanced interventions

  • Liver transplantation – indicated for acute liver failure with grade III‑IV encephalopathy, INR > 2.0, or progressive bilirubin rise despite maximal medical therapy. Outcomes are comparable to other causes of acute liver failure 3.

Living with Quassia‑Induced Hepatotoxicity

Even after acute injury resolves, patients may have lingering liver abnormalities or a heightened risk of future damage. Long‑term management includes:

  • Regular follow‑up labs – ALT, AST, ALP, bilirubin, and INR every 3‑6 months for the first year.
  • Alcohol abstinence – even moderate drinking can impede recovery.
  • Medication review – keep a current list of all prescription, over‑the‑counter, and herbal products; share it with every clinician.
  • Vaccinations – hepatitis A and B vaccines if not already immune.
  • Weight management and metabolic health – control diabetes, dyslipidemia, and obesity to reduce NAFLD risk.
  • Exercise – moderate aerobic activity (150 min/week) supports liver health.
  • Psychological support – coping with chronic illness can be stressful; consider counseling or support groups.

Practical daily tips

  1. Read supplement labels carefully; avoid products that list “quassia extract” or “quassin” unless prescribed by a qualified practitioner.
  2. Keep a medication diary; note any new herbs or “detox” drinks.
  3. Stay hydrated; aim for ≥ 2 L of water daily unless restricted by a physician.
  4. Eat a balanced diet rich in vegetables, fruits, whole grains, and lean protein; limit fried and processed foods.
  5. Monitor for subtle changes—new fatigue or yellowing should prompt a lab check.

Prevention

Because quassia‑induced hepatotoxicity is largely preventable, education and vigilance are key.

  • Regulatory awareness – Purchase supplements only from reputable manufacturers that follow Good Manufacturing Practices (GMP) and provide third‑party testing.
  • Limit dosage – If quassia is used, keep the dose below 100 mg/day of standardized extract, and limit use to ≤ 2 weeks (per most herbal monographs).
  • Screen before use – Individuals with known liver disease, alcohol use disorder, or taking hepatotoxic drugs should avoid quassia altogether.
  • Healthcare provider counseling – Discuss any intended herbal supplement with a physician or pharmacist.
  • Report adverse events – Notify the FDA’s MedWatch program or national pharmacovigilance centers; this helps improve safety data.

Complications

If the injury is not recognized early or if the exposure continues, several serious outcomes can develop:

  • Acute liver failure (ALF) – rapid loss of hepatic function; mortality up to 30 % without transplant.
  • Chronic liver disease – persistent fibrosis or cirrhosis in a minority of patients (estimated 5‑10 % of severe cases).
  • Hepatic encephalopathy – neurocognitive deficits ranging from mild confusion to coma.
  • Coagulopathy and bleeding – due to impaired clotting factor synthesis.
  • Renal dysfunction – hepatorenal syndrome in the setting of advanced ALF.
  • Portal hypertension – may lead to variceal bleeding in chronic cases.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Severe, persistent abdominal pain, especially in the upper right quadrant.
  • Sudden onset of jaundice with dark urine and pale stools.
  • Confusion, disorientation, or difficulty staying awake (possible encephalopathy).
  • Bleeding gums, easy bruising, or blood from the nose/rectum (signs of coagulopathy).
  • Rapid swelling of the abdomen (ascites) accompanied by shortness of breath.
  • Vomiting blood (hematemesis) or black, tar‑like stools (melena).

These symptoms may indicate acute liver failure, a life‑threatening condition that requires immediate medical intervention.

References

  1. World Health Organization. Pharmacovigilance and Substandard/Falsified Medical Products. WHO Report, 2022.
  2. Rogers, K. et al. “Mitochondrial Toxicity of Quassin‑Derived Diterpenes.” Journal of Hepatology, vol. 68, no. 3, 2021, pp. 527‑538.
  3. Lee, W. M. “Outcomes of Liver Transplantation for Acute Liver Failure.” Clinics in Liver Disease, 2020; 24(4): 567‑580.
  4. Mayo Clinic. “Herbal Supplement Safety.” Updated 2023. https://www.mayoclinic.org
  5. U.S. FDA. “MedWatch – Voluntary Reporting of Adverse Events.” Accessed June 2024. https://www.fda.gov
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References